Evidence map›Paper›PMID 36578043›Full record

ArticleJournal of cheminformatics2022

Human-in-the-loop assisted de novo molecular design.

Iiris Sundin, Alexey Voronov, Haoping Xiao, Kostas Papadopoulos, Esben Jannik Bjerrum, Markus Heinonen, Atanas Patronov, Samuel Kaski, Ola Engkvist

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Modeling needs user modeling.Frontiers in artificial intelligence · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Iiris SundinDepartment of Computer Science, Aalto University, Espoo, Finland. iiris.sundin@aalto.fi.
Alexey VoronovMolecular AI, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden. alexey.voronov1@astrazeneca.com.
Haoping XiaoDepartment of Computer Science, Aalto University, Espoo, Finland.
Kostas PapadopoulosMolecular AI, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Esben Jannik BjerrumMolecular AI, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Markus HeinonenDepartment of Computer Science, Aalto University, Espoo, Finland.
Atanas PatronovMolecular AI, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Samuel KaskiDepartment of Computer Science, Aalto University, Espoo, Finland.
Ola EngkvistMolecular AI, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Funding

Academy of Finland 341763AstraZeneca 310303UKRI Turing AI World-Leading Researcher Fellowship EP/W002973/1
6 · The paper itself

Abstract

A de novo molecular design workflow can be used together with technologies such as reinforcement learning to navigate the chemical space. A bottleneck in the workflow that remains to be solved is how to integrate human feedback in the exploration of the chemical space to optimize molecules. A human drug designer still needs to design the goal, expressed as a scoring function for the molecules that captures the designer's implicit knowledge about the optimization task. Little support for this task exists and, consequently, a chemist usually resorts to iteratively building the objective function of multi-parameter optimization (MPO) in de novo design. We propose a principled approach to use human-in-the-loop machine learning to help the chemist to adapt the MPO scoring function to better match their goal. An advantage is that the method can learn the scoring function directly from the user's feedback while they browse the output of the molecule generator, instead of the current manual tuning of the scoring function with trial and error. The proposed method uses a probabilistic model that captures the user's idea and uncertainty about the scoring function, and it uses active learning to interact with the user. We present two case studies for this: In the first use-case, the parameters of an MPO are learned, and in the second use-case a non-parametric component of the scoring function to capture human domain knowledge is developed. The results show the effectiveness of the methods in two simulated example cases with an oracle, achieving significant improvement in less than 200 feedback queries, for the goals of a high QED score and identifying potent molecules for the DRD2 receptor, respectively. We further demonstrate the performance gains with a medicinal chemist interacting with the system.

Indexed as

AI-assisted designDe novo molecular designExpert knowledge elicitationGoal-oriented molecule generationHuman-in-the-loopInteractive algorithmsReward elicitation

Identifiers

PMID36578043
PMCPMC9795720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.